Qiagen NV (QGEN)
NYSE:QGEN
Want to see QGEN full AI Analyst Report?
Top Page
Qiagen
(NYSE:QGEN)
Select Model
Select Model
Rating:65Neutral
Price Target:
$37.00
▼(-10.28% Downside)
Action:DowngradedDate:04/30/26
The score is supported primarily by improved 2025 profitability and solid operating/free cash flow with manageable leverage, plus constructive 2026 guidance. These positives are tempered by very weak technicals (price far below key moving averages and bearish MACD) and some fundamental consistency risks (historical earnings/FCF volatility and near-term headwinds impacting early 2026).
Positive Factors
Recurring consumables and installed‑base pull‑through
A high proportion of revenue comes from single‑use consumables and assay kits that are routinely reordered, creating predictable recurring demand. An installed base of ~31,400 placements supports long‑term consumable pull‑through and revenue resilience across research and clinical customers.
Negative Factors
Earnings and cash‑flow volatility across years
Historic swings in revenue, margins and FCF indicate sensitivity to product cycles, OEM contributions and working‑capital or investment timing. Such variability can restrain planning, increase refinancing risk in stress scenarios, and complicate reliable multi‑year forecasting for investors and managers.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables and installed‑base pull‑through
A high proportion of revenue comes from single‑use consumables and assay kits that are routinely reordered, creating predictable recurring demand. An installed base of ~31,400 placements supports long‑term consumable pull‑through and revenue resilience across research and clinical customers.
Read all positive factors
Qiagen (QGEN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.10B
Dividend Yield3.31%
Average Volume (3M)1.71M
Price to Earnings (P/E)22.8
Beta (1Y)0.63
Revenue Growth5.65%
EPS Growth411.58%
CountryUS
Employees5,700
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)1.98
Shares Outstanding206,074,750
10 Day Avg. Volume1,401,139
30 Day Avg. Volume1,709,211
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.61
Price to Sales (P/S)4.71
P/FCF Ratio21.72
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue3.70
Enterprise Value/Gross Profit5.98
Enterprise Value/Ebitda10.77
Forecast
1Y Price Target
$44.16Price Target Upside7.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)2.46
Revenue Forecast (FY)$2.17B
Qiagen Business Overview & Revenue Model
Company Description
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sampl...
How the Company Makes Money
QIAGEN primarily makes money by selling (1) consumables and kits and (2) instruments and related services/software to laboratories and clinical customers. A large portion of revenue is recurring because many of its products are single-use or repea...
Qiagen Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down sales across regions to reveal where Qiagen is strongest and where growth opportunities or risks lie. Geographic splits expose exposure to local healthcare spending, regulatory environments, pandemic-related demand swings, and currency or market-concentration risks that can materially affect future results.
Breaks down sales across regions to reveal where Qiagen is strongest and where growth opportunities or risks lie. Geographic splits expose exposure to local healthcare spending, regulatory environments, pandemic-related demand swings, and currency or market-concentration risks that can materially affect future results.
Data provided by:
The Fly
The FlyQiagen Earnings Call Summary
Earnings Call Date:Feb 04, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Positive
The call presents a broadly positive operational and financial picture: QIAGEN beat Q4 and full-year outlooks, delivered margin expansion and strong free cash flow, progressed multiple growth pillars (Sample Technologies, QuantiFERON, QIAstat, QIAcuity, QDI), completed strategic acquisitions (Parse, Genoox) and set 2026 guidance for continued profitable growth. Notable near-term challenges include declines in PCR/NGS consumables, regional softness (U.S. and China), tariff and FX headwinds, and short-term dilution from Parse and discontinued product lines that weigh on Q1/first-half 2026. Management expects improvement and acceleration into H2 2026 driven by new product launches and strengthened growth pillars.Positive Updates
Q4 Results Above Outlook
Net sales of $540M in Q4 2025, up 1% at constant exchange rates (CER) and ahead of outlook (which assumed flat sales). Adjusted diluted EPS was $0.62 at CER vs. outlook of about $0.60.
Negative Updates
PCR Product Group Decline
PCR product group sales declined 9% CER in Q4 2025; while QIAcuity consumables grew, sales of other PCR consumables fell due to a cautious funding environment and lower OEM contributions versus 2024.
Read all updates
Q4-2025 Updates
Positive
Negative
Q4 Results Above Outlook
Net sales of $540M in Q4 2025, up 1% at constant exchange rates (CER) and ahead of outlook (which assumed flat sales). Adjusted diluted EPS was $0.62 at CER vs. outlook of about $0.60.
Read all positive updates
Company Guidance
QIAGEN guided 2026 to at least 5% sales growth at constant exchange rates (CER) and adjusted diluted EPS of at least $2.50 at CER, while expecting the adjusted operating income margin to remain about 29.5% (despite ~160 basis points of headwinds from the Parse acquisition, tariffs and FX); currency is expected to be a ~1‑point tailwind to full‑year sales (neutral to EPS) and ~2–3 points tailwind to Q1 sales. For Q1 the company expects net sales growth of at least 1% CER versus Q1‑25 ($483 million) and adjusted EPS of at least $0.54 at CER (vs $0.55 a year ago), noting Q1 headwinds of roughly $10M from the discontinuation of NeuMoDx/Dialunox (~2 percentage points), ~$10M from cautious life‑science spending (~2 points), and a low‑single‑digit QuantiFERON comparison (≈$6–7M, ~1 point); Parse will dilute Q1 EPS by ~$0.02 and U.S. tariffs by ~ $0.02. Management expects H1 growth of roughly 2–3% CER with an H2 acceleration to reach the full‑year target, a normalized run rate near 6% CER after roll‑offs, a currency‑neutral EPS impact, and continued focus on growth pillars (targeting ~9% CER growth in 2026 with Sample Technologies ≈ $720M, QuantiFERON ≈ $535M, QIAstat ≈ $160M, QIAcuity ≈ $100M and QDI ≈ $125M); the company completed a $500M share repurchase in January and shows pro‑forma leverage of ~1.3x net debt/adjusted EBITDA.Qiagen Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
70
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.09B | 1.98B | 1.97B | 2.14B | 2.25B |
| Gross Profit | 1.29B | 967.35M | 1.23B | 1.38B | 1.45B |
| EBITDA | 717.27M | 368.26M | 688.55M | 779.36M | 895.24M |
| Net Income | 424.88M | 83.59M | 341.30M | 423.21M | 512.60M |
Balance Sheet | |||||
| Total Assets | 6.30B | 5.69B | 6.12B | 6.29B | 6.15B |
| Cash, Cash Equivalents and Short-Term Investments | 1.10B | 1.15B | 1.06B | 1.42B | 1.07B |
| Total Debt | 1.65B | 1.61B | 1.69B | 2.03B | 2.12B |
| Total Liabilities | 2.52B | 2.12B | 2.31B | 2.82B | 3.05B |
| Stockholders Equity | 3.78B | 3.57B | 3.81B | 3.47B | 3.10B |
Cash Flow | |||||
| Free Cash Flow | 453.28M | 506.38M | 296.65M | 565.93M | 432.47M |
| Operating Cash Flow | 654.33M | 673.55M | 459.45M | 715.26M | 639.00M |
| Investing Cash Flow | -305.28M | -249.23M | -87.66M | -726.76M | -202.43M |
| Financing Cash Flow | -178.98M | -422.90M | -433.83M | -125.80M | -150.37M |
Qiagen Technical Analysis
Negative
41.24
Price Trends
44.25
Negative
46.28
Negative
46.83
Negative
Market Momentum
-0.61
Negative
45.99
Neutral
61.25
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QGEN, the sentiment is Negative. The current price of 41.24 is above the 20-day moving average (MA) of 40.55, below the 50-day MA of 44.25, and below the 200-day MA of 46.83, indicating a neutral trend. The MACD of -0.61 indicates Negative momentum. The RSI at 45.99 is Neutral, neither overbought nor oversold. The STOCH value of 61.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QGEN.
Qiagen Risk Analysis
Qiagen disclosed 38 risk factors in its most recent earnings report. Qiagen reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Qiagen Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $45.69B | 40.41 | 70.87% | ― | 13.08% | 25.40% | |
70 Outperform | $21.57B | 34.48 | 33.99% | ― | 1.25% | ― | |
67 Neutral | $175.76B | 26.66 | 13.26% | 0.30% | 5.36% | 6.54% | |
65 Neutral | $7.10B | 22.80 | 11.85% | 3.31% | 5.65% | 411.58% | |
65 Neutral | $29.45B | 26.20 | 22.46% | ― | 7.33% | 9.79% | |
62 Neutral | $11.08B | 60.67 | 3.28% | 0.29% | 4.79% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
QGEN
Qiagen
34.44
-7.57
-18.02%
IDXX
Idexx Laboratories
579.23
89.25
18.22%
ILMN
Illumina
142.58
63.00
79.17%
RVTY
Revvity
99.09
6.46
6.97%
TMO
Thermo Fisher
472.95
63.68
15.56%
IQV
IQVIA Holdings
176.47
23.18
15.12%
Qiagen Corporate Events
Qiagen Tops 2025 Guidance and Sets Ambitious 2026 Growth Targets
Feb 6, 2026
On February 4, 2026, Qiagen reported unaudited results for the fourth quarter and full year ended December 31, 2025, posting Q4 net sales of $540 million, up 4% year on year (1% at constant exchange rates), and diluted EPS of $0.49, with adjusted ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.